Desirable cell death during anticancer chemotherapy - PubMed (original) (raw)

Review

doi: 10.1111/j.1749-6632.2010.05763.x.

Rosa Conforti, Laetitia Aymeric, Yuting Ma, Takahiro Yamazaki, Sylvie Rusakiewicz, Antoine Tesnière, François Ghiringhelli, Lionel Apetoh, Yannis Morel, Jean-Philippe Girard, Guido Kroemer, Laurence Zitvogel

Affiliations

Review

Desirable cell death during anticancer chemotherapy

Clara Locher et al. Ann N Y Acad Sci. 2010 Oct.

Abstract

The concept of immunogenic chemotherapy that has recently emerged relies upon the capacity of a cytotoxic compound to trigger a cell-death modality. This modality elicits cross-priming by dendritic cells of tumor antigen-specific T cells that will contribute to the tumoricidal activity of the compound and protect the host against relapse. In contrast, most anticancer drugs elicit nonimmunogenic apoptosis that is not accompanied with an immunizing property. This review will discuss some molecular and metabolic changes required at the level of the tumor that must engage key pathways at the level of the host for the induction of Tc1 polarized-protective T cell responses during chemotherapy. We will summarize the immune adjuvants that can boost the immunogenicity of cell death to augment the efficacy of chemotherapy.

© 2010 New York Academy of Sciences.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources